Featured White Papers
- Oct. 14th: Simplified IT with Software-as-a-Service (SaaS) (ZDNet)
- PCI DSS therapy for the smaller retailer (McAfee)
- The rise of Web commuting (Citrix Online)
Health Care Industry
Industry: Email Alert RSS FeedBid to remove biopsy barrier to hep C treatment.
Australian Doctor, January, 2006
 | Content provided in partnership with |  |
By Bianca Nogrady
PATIENTS with hepatitis C will no longer need a liver biopsy to qualify for subsidised treatment with antiviral drugs if a December Pharmaceutical Benefits Advisory Committee recommendation is approved.
The PBAC has recommended that liver biopsy be removed as a requirement before patients are eligible for treatment with peginterferon alfa-2b plus oral ribavirin (Pegatron Combination Therapy).
Associate Professor Greg Dore, an infectious diseases physician at St Vincent's Hospital in Sydney, said the proposed move was significant because it could increase ...
Read the rest of this article with a Free Trial at HighBeam Research.Find Research Guides for:
Find Featured Titles for: Business
- Academy of Marketing Science Review
- Accounting Historians Journal, The
- Accounting History
- AgExporter
- Agricultural Research
- Agricultural and Resource Economics Review
- Air Force Comptroller
- Air Safety Week
- Airline Industry Information
- American Demographics
- American Journal of Potato Research
- Architectural Review, The
- Asian Economic News
- Entrepreneur
Most Popular Articles in Health
- Fuel your workout: exercisers who eat before they work out have more energy ...
- Soothe a dry, itchy scalp: 5 easy expert solutions
- Cocktails and calories: Beer, wine and liquor calories can really add up. ...
- The sour truth about apple cider vinegar - evaluation of therapeutic use
- The, six best supplements you've never heard of: these secret weapons can ...
- More »